The Life Sciences team guided Freenome on a strategic collaboration agreement with Roche to commercialize Freenome’s cancer screening technology in international markets. In addition, Freenome will evaluate Roche’s forthcoming Sequencing by Expansion (SBX) technology for future development applications. Roche is acquiring exclusive ex-U.S. rights to develop “kitted” tests, which involve packaging the software and assay to enable decentralized test processing and analysis, without a large, centralized processing lab. Roche is the global leader in decentralized testing, and this partnership will accelerate the availability of Freenome’s tests in certain ex-U.S. markets. Freenome retains rights to ex-U.S. centralized testing as well as all U.S. rights, subject to its pre-existing license to Exact Sciences.
Freenome is breaking barriers to early cancer detection with a suite of blood-based tests built on its multiomics platform. The company recognizes that no single technology can identify every cancer due to the disease’s inherent heterogeneity. Freenome’s multimodal approach combines molecular biology and assays with computational biology, machine learning and multiple data types to tune into cancer’s subtlest cues, even at the earliest stages of the disease. With the convenience of a standard blood draw, Freenome aims to empower everyone to access recommended cancer screenings. The company is partnering with healthcare organizations and population health decision-makers to integrate its technology and software platform, making cancer detection easier and more accessible.
The Goodwin team was led by Shane Albright, Sarah Ashfaq, Katie Hand, and Kingsley Taft, and also included Nancy Urizar, Alan Wang, and William Jackson.
For more information on the deal, please read the press release.